Cervical cancer screening rates (%)			HPV vaccination rates (%)
Year	Commercial PPOs	Commercial HMOs	Medicaid HMOs	Commercial PPOs	Commercial HMOs	Medicaid HMOs
1999	–	71.8	–	–	–	–
2000	–	78.1	–	–	–	–
2001	–	80.0	61.1	–	–	–
2002	–	80.5	62.2	–	–	–
2003	–	81.8	64.0	–	–	–
2004	–	80.9	64.7	–	–	–
2005	74.6	81.8	65.2	–	–	–
2006	72.6	81.0	65.7	–	–	–
2007	73.5	81.7	64.8	–	–	–
2008	74.0	80.7	66.0	–	–	–
2009	74.6	77.3	65.8	–	–	–
2010	74.5	77.0	67.2	–	–	–
2011	74.4	76.5	66.7	–	–	–
2012	73.6	75.5	64.5	–	–	–
2014	73.8	76.3	60.2	–	–	–
2015	71.7	74.7	55.8	–	–	–
2016	73.0	74.3	58.0	13.9	16.7	22.7
2017	73.2	74.3	59.4	22.0	25.7	35.3
2018	73.5	75.2	59.3	24.8	29.8	37.8
2019	74.2	76.2	60.1	27.2	31.9	40.1
2020	72.4	73.8	56.8	29.2	33.4	39.9

^*The HEDIS® cervical cancer screening measure was updated in 2013 to reflect new guidelines from the US Preventive Services Task Force. Prior to 2013, the cervical cancer screening measure assessed women 21–64 years of ages who had cervical cytology performed within the last 3 years. Since 2013, the measure assesses women who were screened for cervical cancer using any of the following criteria: women 21–64 years of age who had cervical cytology performed within the last 3 years; women 30–64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years; and women 30–64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last 5 years.

Source:

^1.National Committee for Quality Assurance. Healthcare Effectiveness Data and Information Set (HEDIS®) measures. Cervical cancer screening. https://www.ncqa.org/hedis/measures/cervical-cancer-screening/

^2.National Committee for Quality Assurance. Healthcare Effectiveness Data and Information Set (HEDIS®) measures. Immunizations for Adolescents (IMA). Human Papillomavirus for Adolescents. https://www.ncqa.org/hedis/measures/immunizations-for-adolescents/